
Medical Plenary: Hemophilia treatment in 2030
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.
Year: 2024
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The World Federation of Hemophilia (WFH) Shared decision-making (SDM) tool helps clinicians and people with hemophilia work together to make treatment decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
Listen to three free 90-minute webinars covering the different hemophilia treatments and the applications of this important tool for healthcare practitioners and people with hemophilia.
Listen to this free 90-minute webinar covering the different aspects and applications of factor and non-factor hemophilia treatments, such as standard half-life (SHL), extended half-life (EHL), bispecific antibody, and rebalancing agent products, and gene therapy.
Speakers for the session will include Glenn Pierce, MD, PhD, Vice President, Medical, WFH; Barbara Konkle, MD, WFH Board Member; and Steven Pipe, MD. Participants will also have the opportunity to hear testimonials from people with hemophilia, Enrique Preza and Hazri Aris, who have made treatment changes.
Listen to this free 90-minute webinar on how to consider the benefits and risks of factor and non-factor treatments available for hemophilia.
Speakers for the session will include Glenn Pierce, MD, PhD, Vice President, Medical, WFH; Barbara Konkle, MD, WFH Board Member; and Steven Pipe, MD. Participants will have the opportunity to hear testimonials from people with hemophilia, Garrett Hayes and Jay Konduros, who have made treatment changes.
Listen to this free 90-minute webinar on the advantages of using shared decision-making for people with hemophilia and for healthcare providers, including real-life experiences of HCP and PWH using the WFH SDM Tool.
Speakers for the session will include Donna Coffin, Sara Garcia Barcenilla and Mariette Driessens. Presentations were followed by a panel discussion, with insight from Glenn Pierce, MD, PhD, Barbara Konkle, MD, Hazri Aris, Jay Konduros, Garrett Hayes and Enrique Preza.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.

This eLearning module presents Section 4 of the WFH Guidelines for the Management of Hemophilia: Hemostatic Agents. Detailed illustrations, interactive

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been

A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which